Core Viewpoint - Clover Biopharmaceuticals-B (02197) has seen a significant stock increase of over 21%, currently trading at 2.75 HKD with a transaction volume of 42.22 million HKD, following the announcement of its clinical trial progress for respiratory vaccines [1] Group 1: Company Developments - In June, Clover Biopharmaceuticals announced the initiation of Phase I clinical trials for its respiratory combination vaccine candidates SCB-1022 (RSV+hMPV) and SCB-1033 (RSV+hMPV+PIV3) [1] - The CEO of Clover Biopharmaceuticals, Liang Guo, highlighted that while currently approved recombinant protein RSV vaccines are safe and effective, there remains a significant unmet clinical need globally [1] Group 2: Market Context - The unmet clinical needs include the inability to prevent and alleviate respiratory diseases caused by human metapneumovirus (hMPV) and parainfluenza virus type 3 (PIV3), which are structurally similar to RSV [1]